Copyright 2018 IIF Management Company LLC.  All rights reserved.  “Illumina” and “Illumina Ventures” are trademarks of Illumina, Inc. and are used herein with their permission.  All other company names, logos, and other trademarks are the property of their respective owners.

Recent News

Comprehensive technologies are always intriguing because they can answer many questions at once. Next generation sequencing doesn’t read a few genes, it can read all of them. 

As researchers continue to push the boundaries of science, gentle cell sorting is becoming increasingly important. Accelerated research in regenerative medicine, gene editing, single-cell genomics and other areas require sorting sensitive and fragile cell types. 

Cradle Genomics, inventors of a novel prenatal testing methodology, today announced the close of a highly successful Series A funding round of $17.1 million with select investors.

One of the keys to diagnosing and treating cancer is understanding the disease on the single cell level. Quite often, damaged cells can be poised on the cliff, uncertain whether to become malignant or take a more benign path.

Stilla Technologies announced today the successful completion of a Series A financing round of 16 million euros ($18 Million) led by Illumina Ventures.

Ribometrix out of Durham, NC, today announced a $30 million Series A round of financing to fund the development of small molecule drugs targeting RNA involved in cancer and neurodegeneration.

SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, announced the completion of an oversubscribed $72 million Series C financing.

Luna DNA, the first community-owned genomic and medical research database, today announced financing from key investors Illumina Ventures and Arch Venture Partners.

Cernostics, a privately-held company focused on delivering next-generation cancer diagnostics and prognostics, announced today that it has raised $2.5 million in Series A1 financing, led by Illumina Ventures.

The First National Medical Practice Focused on Genomics Has Now Raised More Than $23 Million in Financing to Improve Access to Genetic Services.

NanoCellect Biomedical Inc., a developer of microfluidic cell sorting technologies for cell-based assays, today announced the completion of a $10 million Series B financing round, including convertible notes.

Biota Technology, the oilfield DNA sequencing pioneer, has achieved a critical milestone on its path to commercialization: the diagnostic has been deployed by a majority of the top 20 US shale producers in the United States.

Synthetic DNA manufacturer DNA Script has today announced a Series A fundraising of 11 million euros ($13 million) led by Illumina Ventures with additional investments from M Ventures, the corporate venture arm of Merck KGaA, Darmstadt, Germany, plus existing investors Sofinnova Partners, Kurma Partners, and Idinvest Partners...

SerImmune Inc. today announced an $8 million round of financing, led by Illumina Ventures, with participation from Merck, known as MSD outside the United States and Canada, through a subsidiary, and additional undisclosed investors...

Genetic testing has exploded, but there's a shortage of genetic counselors to interpret the results. A new start-up called Genome Medical wants to fix that...

The nodding donkey was invented nearly a century ago, and it’s still hard at work in the oil patch, virtually unchanged, pumping oil out of the ground. There’s been a recent innovation, though: Algorithms adjust the extraction flow based on computer monitoring hundreds of feet below...

Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced Microsoft Corp. will purchase ten million strands of DNA from Twist Bioscience for expanded digital data storage research...

The U.S. Food and Drug Administration granted 23andMe authorization to offer ten genetic health risk reports including late-onset Alzheimer’s disease, Parkinson’s disease, celiac disease, and a condition associated with harmful blood clots...

The U.S. Food and Drug Administration today permitted marketing of the Seeker System for the screening of four, rare Lysosomal Storage Disorders (LSDs) in newborns...

Good Start Genetics, developers of best-in-class genetic sequencing solutions for growing families, continues its commitment to democratize genetic testing by including high quality genetic counseling with all its tests...

Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced Microsoft Corp. has agreed to purchase ten million long oligonucleotides from Twist Bioscience to encode digital data...

Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, has won the 2016 Bio-IT World Best Practice Award for its HLI Knowledgebase™, a key tool in the company’s portfolio to transform how medicine is practiced...

Twist Bioscience Corporation, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced the acquisition of Genome Compiler Corporation, an Israeli-based company providing software for genetic engineers, molecular and synthetic biologists...

23andMe, Inc., the leading personal genetics company, today announced that the National Institutes of Health (NIH) has funded a promising new study by scientists at 23andMe that could help alleviate some of the existing disparities in genetics research between people of European ancestry and people of African, Latino and Asian ancestry...

Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, announced today that the company has completed an offering of Series B Preferred Stock, raising in excess of $220 million...

Desktop Genetics, a London-based software company won the SXSW award for its DESKGEN platform, a comprehensive CRISPR research tool that uses laboratory-validated gene-editing techniques to generate optimized approaches to modify any gene, in any cell, in any species....

Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced the completion of a $61 million Series D private financing...

Twice in the past year, Adaptive Biotechnologies raised a truckload of cash. The first time, the company invested in its cutting-edge immune system sequencing...

Kallyope Inc., a biotechnology company focused on harnessing the potential of the gut-brain axis, today announced that it has launched with Series A financing of $44 million...

Desktop Genetics Ltd, a software company revolutionizing the way biologists use CRISPR gene editing technology, announced today that it has received investment funding from Illumina, Inc., the global leader in next-generation sequencing technology...

23andMe, Inc., the leading personal genetics company, today announced it has raised $115 million in a Series E financing led by Fidelity Management & Research Company...

Goldman Sachs is recognizing Ramji Srinivasan, founder and CEO of health technology company Counsyl, as one of the 100 Most Intriguing Entrepreneurs of 2015 at its Builders + Innovators Summit in Santa Barbara, California...

Counsyl, a health technology company that offers DNA screening for diseases that can impact women, men, and their children, announced today that the company has screened more than 500,000 patients, doubling the number of patients served since May 2014...

Illumina, Inc. today announced it has signed a definitive agreement to acquire GenoLogics Life Sciences Software, a developer of industry-leading laboratory information management systems for life sciences organizations. The acquisition strengthens Illumina’s industry leading portfolio of genetic analysis solutions...

Baebies, Inc. today announced the completion of a round of equity financing totaling $13 million. The oversubscribed round of financing included key investors Rex Health Ventures, DUMAC, LLC (managers of the Duke endowment), Cunning Capital, Triad, LLC, the Duke Angel Network and a loan from the North Carolina Biotechnology Center. Many of Advanced Liquid Logic’s (ALL) former investors including Charleston Angel Partners, and Baebies’ executive team, also invested...

Please reload

Current Illumina Ventures portfolio:

Biota applies DNA sequencing and data science to explore the earth’s subsurface. We provide
actionable insights to the oil industry for maximizing reservoir production and reducing environmental impact. Biota enhances multimillion-dollar decisions with DNA data services for production profiling, sweet spot identification, and reservoir connectivity. This novel information source improves both profitability and sustainability.

Cernostics is a leader in tissue-based diagnostic testing, providing diagnostic tests with deeper tissue insights, better patient outcomes and lower cost of care. Their mission is to quantify the complexity of the tissue system, providing physicians and patients with individualized, actionable information to improve outcomes and reduce the incidence and mortality of cancer.

DNA Script is a leading company in manufacturing de novo synthetic nucleic acids using an enzymatic technology. The company aims at accelerating innovation in life science and technology through rapid, affordable, and high-quality DNA synthesis. DNA Script's approach leverages nature's billions of years of evolution in synthesizing DNA to set a new standard for how DNA is made and accelerate the adoption of synthetic biology across diverse disciplines such as biopharma, sustainable chemistry and crop science.

Harnessing the regulatory genome to create next-generation molecular therapies.

Genome Medical, Inc. is a network of clinical genetics experts integrating genomics into everyday health care. We enable patients and clinicians to navigate the rapidly evolving field of genomics to improve health, diagnose and prevent disease, and lower the cost of care. Our goal is to bridge the gap between genomic technology and medical practice by creating scalable, efficient models for lifelong genome-centered health care.

Kallyope is focused on the identification of new therapeutic and consumer opportunities involving the gut-brain axis, the information highway between our gut and our brain. Founded and headquartered in New York City, Kallyope is integrating cutting-edge technologies including single cell sequencing, optogenetics, neural imaging and bioinformatics into a platform that will decode and translate gut-brain circuits, changing the way we think about food, nutrition, and human physiology.

Luna DNA is the first genomic and medical research database owned by its community. A Public Benefit Corporation, Luna DNA enables people to share their health data for medical research for the greater good of the community. 

NanoCellect develops microfluidic technology for cell based assays. NanoCellect’s WOLF cell sorter and N1 single cell plate dispenser allows researchers to perform antibody discovery, cell line development, genomic sample preparation and CRISPR genomic editing faster, safer, and without contamination.

Ribometrix is a platform therapeutics company discovering small molecule drugs that target functional 3D RNA structures to treat human diseases.

SerImmune reveals the compositions of functional immune repertoires, creating new opportunities for therapeutic and diagnostic development. SerImmune maps the distinct antibodies within a repertoire to antigens associated with infections, allergens, microbiome organisms, autoimmune diseases, and cancers.

SQZ Biotechnologies is a cell therapy company developing novel treatments for multiple therapeutic areas. The SQZ platform directly engineers complex cell functions without affecting cell health, with a simple and scalable process.  The therapeutic platform can bring cell therapies into indications where new and innovative treatments are needed the most.

Stilla Technologies focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity for all areas of the life sciences.

At Twist Bioscience, our expertise is accelerating science and innovation by leveraging our proprietary semiconductor-based synthetic DNA manufacturing process featuring a 10,000-well silicon platform to deliver cost-effective, rapid, high-quality and high throughput gene production, to expedite the design, build, test cycle to enable personalized medicines, pharmaceuticals, industrial chemicals, improved agriculture production, diagnostics, biodetection and data storage.

Investments made by Illumina, Inc. prior to the launch of Illumina Ventures:

23andMe, Inc. is the leading personal genetics company. Founded in 2006, the mission of the company is to help people access, understand and benefit from the human genome. 23andMe offers the first and only genetic service available directly to consumers that includes reports that meet FDA standards. More than one million customers worldwide have been genotyped by 23andMe, with over 80 percent consented to participate in research.

Ariosa Diagnostics, Inc. is a leading global molecular diagnostics company committed to improving overall patient care by developing and delivering innovative, affordable, and widely-accessible testing services through its CLIA laboratory. Ariosa has developed leading-edge technologies to perform a directed analysis of cell-free DNA in blood.

 

Ariosa was acquired by Roche in 2015.

Baebies provides timely, inexpensive and flexible testing for a wide range of pediatric diseases, particularly through newborn screening. We are bringing new technology, new tests, and new hope to children and their parents worldwide. At Baebies, we believe everyone deserves a healthy start.  

Boreal Genomics develops novel tools for cancer diagnostics and life sciences research based on a platform for enrichment and purification of nucleic acids licensed from the University of British Columbia in 2007. Boreal has commercialized two products, one for purification of highly contaminated DNA samples with applications in environmental metagenomics and forensics, and the second for enrichment of circulating tumor DNA in the rapidly growing “liquid biopsy” field for therapy selection, monitoring, and early detection of cancer.

CareDx, Inc. is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients. The company has commercialized AlloMap®, a gene expression test that aids clinicians in caring for heart transplant patients. The company also develops AlloSure, a donor-derived cellfree DNA based surveillance solution for Kidney Transplant patients.

 

CareDx had a successful IPO in 2015.

Counsyl is a health technology company that offers DNA testing for diseases that can impact men, women and their children. The Counsyl philosophy is simple: screen for diseases where advanced knowledge makes a difference in health outcomes, whether it’s changing a behavior, pursuing preventative measures, or simply preparing for what lies ahead.

Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using their unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.

 

deCODE genetics was acquired by Amgen in 2012.

Desktop Genetics is a UK-based software company building a CRISPR AI that enables scientists to modify any cell, in any species by designing and executing personalized CRISPR genome editing, right from their desktop.

GenoLogics is a leading provider of laboratory information management system (LIMS) software specifically designed for use with genomics technologies in regulated and unregulated labs. Clarity LIMS offers quick implementation, an intuitive role-optimized interface, and features that make it an invaluable investment for labs that are regulated and utilizing NGS and other genomics technologies.

 

Genologics was acquired by Illumina in 2015.

Helixis developed and manufactured a low cost, high performance realtime PCR instrument based on a technology developed at Caltech by Nobel Laureate David Baltimore. 

 

Helixis was acquired by Illumina in 2010.

Human Longevity, Inc. (HLI), is creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data, and by applying large scale computing and machine learning to this data, HLI is making novel discoveries which will revolutionize the practice of medicine. HLI’s business also includes the HLI Health Nucleus™, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health.

Sequenta was a biotech company dedicated to the discovery and development of clinical diagnostics based on a revolutionary new platform for understanding immune system status. A profound reduction in the cost of DNA sequencing enabled the company to develop brand new approaches to measuring the most variable part of the human genome: the immune cell receptor genes.

 

Sequenta was acquired by Adaptive Biotechnologies in 2015.

SpeeDx is an innovative Molecular Diagnostics company with class leading multiplexing technology. From highly multiplexed detection assays for Infectious diseases to characterizing SNPs related to antibiotic resistance, SpeeDx is pushing the limits of qPCR and creating more actionable information for laboratories and clinicians alike.

Cradle Genomics proprietary assay is based on the genetic analysis of fetal material that are quickly collected during a first trimester visit with no risk to the mother or developing fetus. Headquartered in San Diego with additional R&D operations in Detroit, Cradle Genomics is dedicated to the transformation of NIPT by offering the most comprehensive fetal genetic analysis and pregnancy health screening solutions at the earliest stages of pregnancy.